Drug-Drug Interactions with Consideration of Pharmacogenetics

Shogo Ozawa
2018 Yakugaku zasshi  
Elderly patients often suŠer from a variety of diseases and therefore may be prescribed several kinds of drugs. Interactions between these drugs may cause problems in some patients. Guidelines for drug interactions were released on July 8, 2014"Drug Interaction Guideline for Drug Development and Labeling Recommendations (Final Draft)". These guidelines include the theoretical basis for evaluating the mechanisms of drug interaction, the possible extent of drug interactions, and take into
more » ... ation special populations (e.g., infants, children, elderly patients, patients with hepatic or renal dysfunction, and subjects with minor deˆcient alleles for drug metabolizing enzymes and drug transporters). In this symposium article, I discuss this last special population: altered drug metabolism and drug interactions in subjects with minor alleles of genes encoding deˆcient drug metabolizing enzymes. I further discuss a drug label for eliglustat (Cerdelga) with instructions for patients with ultra-rapid, extensive, intermediate, and poor metabolizer phenotypes that arise from diŠerent CYP2D6 gene alleles.
doi:10.1248/yakushi.17-00191-5 pmid:29503430 fatcat:sfcn4fp4orfutkxnuban25oyk4